Latest Conference Coverage

UK Analysis Shows Low Transthyretin Levels Linked to Increased Risk of Multiple Diseases

A recently presented biobank data analysis showed associations between reduced transthyretin and higher incidence of conditions such as Alzheimer disease, cardiovascular disease, and rheumatoid arthritis.

Investigational Imlifidase Shows Rapid and Sustained Improvement of Guillain-Barré Syndrome Symptoms

Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.

Efficacy of CIDP Treatments Immunoglobulin 10% and Efgartigimod Compared Through Matching-Adjusted Indirect Analysis

A recently presented matching-adjusted indirect comparison assessed outcomes of immune globulin subcutaneous (Human)-ifas, 10% solution versus subcutaneous efgartigimod in patients with CIDP.

A More Selective Immune Approach to CIDP With Riliprubart: Claudia Sommer, MD

The president-elect of the Peripheral Nerve Society provided clinical context the mechanism and clinical relevance of riliprubart, a targeted complement inhibitor in development for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 3 minutes]

Carbazole-Based Therapy Carba1 Demonstrates Improvement of Chemotherapy-Induced Neuropathy

Carba1 showed promise in preclinical models as a dual-action agent, protecting against chemotherapy-induced neuropathy while preserving anticancer efficacy and safety.

Phase 2 ARDA Findings Support Development of Empasiprubart in Multifocal Motor Neuropathy

Presented at the 2025 PNS Annual Meeting, phase 2 ARDA data showed empasiprubart reduced IVIg retreatment risk and improved grip strength in patients with MMN.

CIDP Agent Riliprubart Reduces Neurofilament Light in Phase 2 Subanalysis

New data from a phase 2 study presented at the 2025 PNS Annual Meeting showed that riliprubart reduced plasma NfL levels in CIDP, with greater reductions linked to stronger functional improvements.

Tanruprubart Shows Early, Sustained Quality-of-Life Improvements in Phase 3 GBS Trial

Patients with Guillain-Barré syndrome treated with tanruprubart, formerly known as ANX005, reported significant benefits in mobility, self-care, and usual activity compared with placebo.

CRISPR Gene Therapy Nexiguran Ziclumeran Shows Promise in Early-Stage Study of ATTR Amyloidosis With Polyneuropathy

A groundbreaking CRISPR therapy shows promise in treating hereditary ATTR amyloidosis, achieving significant serum TTR reductions and stable patient outcomes.

Key Sessions and Real-World Case Learning at PNS 2025: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting shared key sessions and trends clinicians should follow at the upcoming meeting, emphasizing collaboration, trial data, and clinical relevance. [WATCH TIME: 3 minutes]

Translational Science Reshaping the 2025 PNS Annual Meeting Agenda: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting discussed how this year’s meeting reflects a growing emphasis on therapeutic research and translational progress in peripheral neuropathies. [WATCH TIME: 2 minutes]

Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

Advancing MS Care Through Early Intervention and Deeper CNS Insights: Jack P. Antel, MD

The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. [WATCH TIME: 4 minutes]

Newborn Screening, Enzyme Delivery, and the Future of Pompe Disease Treatment

Priya Kishnani, MD, division chief of Medical Genetics at Duke University, reflects on Pompe disease’s historical and scientific evolution, from early enzyme therapy to next-generation treatment strategies and newborn screening breakthroughs.

Insights on Quanterix Simoa Assay to Diagnose Alzheimer Disease: Mark Roskey, PhD

The chief scientific officer at Quanterix gave a clinical overview on how the company’s Simoa platform enables ultrasensitive detection of neurodegeneration biomarkers in blood, transforming Alzheimer and Parkinson disease research. [WATCH TIME: 3 minutes]

New Treatments, Global Collaboration Highlight 2025 Peripheral Nerve Society Annual Meeting

Committee chairs Vincent Timmerman, PhD, MSc, and Kathrin Doppler, MD, provide a preview of the 2025 PNS Annual Meeting, giving clinicians an inside look at what to expect from the upcoming conference.

The Role of Aging in Multiple Sclerosis Care

Experts discussed how aging impacts multiple sclerosis management, treatment decisions, and overall patient health. [WATCH TIME: 5 minutes]

AI and Machine Learning in MS: Promise and Practicality for Clinical Practice

Experts discussed the current and future applications of AI and machine learning in multiple sclerosis research and clinical care, highlighting both opportunities and limitations. [WATCH TIME: 9 minutes]

Emerging Therapies and the Future of MS: Insights on BTK Inhibitors and CAR T-Cells

Experts discussed the promise and uncertainty surrounding BTK inhibitors and CAR T-cell therapy in addressing progressive multiple sclerosis. [WATCH TIME: 8 minutes]

Evolving Approaches to the Diagnosis and Management of Paraneoplastic Neurologic Syndromes: Ditte Primdahl, MD; Shailee Samir Shah, MD

A duo of experts from Feinberg School of Medicine discussed the growing role of clinical algorithms, risk stratification, and treatment considerations in managing paraneoplastic neurologic syndromes alongside cancer therapies. [WATCH TIME: 4 minutes]

Tailoring Precision Medicine Treatment of Hemorrhagic Stroke Through Predictive Models: Kara R. Melmed, MD

The clinical associate professor of neurology and neurosurgery at NYU Langone talked about the promise of machine learning in identifying patients at high risk for hematoma expansion to guide care. [WATCH TIME: 2 minutes]

Enhancing Brain Plasticity by Personalized and Closed-Loop Neuromodulation: Roy H. Hamilton, MD, MS, FAAN

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the evolving role of noninvasive neuromodulation in promoting brain plasticity. [WATCH TIME: 3 minutes]

Evolving Evidence and Clinical Confidence for Blood Pressure Management in Intracerebral Hemorrhage: Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS

The clinical professor of stroke neurology and neurocritical care at Stanford University discussed the shifting perspective on early blood pressure lowering in intracerebral hemorrhage. [WATCH TIME: 4 minutes]

MDA Ambassador Sunny Brous: Progress, Advocacy, and Connection in ALS

Sunny Brous, a patient advocate living with ALS, shared how her decade-long journey with the disease shaped her mission to build connection, advocate for change, and empower the ALS community.

Evolving Clinical Insights Into Neuroimmune Mechanisms and Multiple Sclerosis Progression

Jack P. Antel, MD, professor of neurology and neurosurgery at McGill University, reflected on key advances in neuroimmune research and their implications for understanding and treating MS.

Episode 140: Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Elizabeth Head, PhD. [LISTEN TIME: 20 minutes]

Illuminating Genetic Insights in Parkinson Disease Through PD GENEration: James Beck, PhD

The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]

Advancing MS Research Through Recognition and Innovation: The John Dystel Prize

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements.

Advancing NMOSD Care for Patients: Treatment Access, Education, and Holistic Well-Being

Sumaira Ahmed, founder and executive director of The Sumaira Foundation, discussed how FDA-approved therapies transformed the NMOSD treatment landscape and highlighted ongoing challenges in patient care.

Prioritizing Brain Health in NMOSD Beyond Disease-Modifying Therapies: Sumaira Ahmed

The founder and executive director of the Sumaira Foundation emphasized the critical role of lifestyle factors such as sleep, exercise, and nutrition for maintaining brain health in patients with NMOSD. [WATCH TIME: 3 minutes]